트레비 테라퓨틱스 (TRVI)

07:30 AM

Trevi Therapeutics to Present Haduvio Development at Piper Sandler Healthcare Conference | TRVI Stock News - StockTitan

07:30 AM

Nov 16, 2024

Trevi Therapeutics to Participate in Upcoming April Events - GuruFocus.com

Nov 16, 2024

Nov 16, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages - Defense World

Nov 16, 2024

Nov 14, 2024

Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow

Nov 14, 2024

Nov 13, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Average PT from Brokerages - MarketBeat

Nov 13, 2024

Nov 12, 2024

How Do Things Look For Trevi Therapeutics Inc (NASDAQ: TRVI) In The Short-Term? - Stocks Register

Nov 12, 2024

Nov 12, 2024

Trevi Therapeutics Announces Proposed Public Offering - Quantisnow

Nov 12, 2024

Nov 12, 2024

Trevi Therapeutics to Participate in Upcoming September Events - Quantisnow

Nov 12, 2024

Nov 12, 2024

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Quantisnow

Nov 12, 2024

Nov 12, 2024

Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences - Quantisnow

Nov 12, 2024

Nov 11, 2024

FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - MarketBeat

Nov 11, 2024

Nov 11, 2024

Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings - Defense World

Nov 11, 2024

Nov 08, 2024

Earnings call: Trevi Therapeutics reports Q3 2024 financials, clinical updates - Investing.com

Nov 08, 2024

Nov 08, 2024

Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat

Nov 08, 2024

Nov 08, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 08, 2024

Nov 08, 2024

Earnings call: Trevi Therapeutics reports Q3 2024 financials, clinical updates By Investing.com - Investing.com UK

Nov 08, 2024

Nov 07, 2024

Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: - GuruFocus.com

Nov 07, 2024

Nov 07, 2024

Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... - Yahoo Finance

Nov 07, 2024

Nov 07, 2024

Trevi Therapeutics Reports Q3 2024 Progress and Financials - TipRanks

Nov 07, 2024

Nov 06, 2024

Trevi Therapeutics Advances Clinical Trials Despite Widening Q3 Losses; Cash Runway Extended | TRVI Stock News - StockTitan

Nov 06, 2024

Nov 06, 2024

Rosalind Advisors Inc. Sells 641,577 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat

Nov 06, 2024

Nov 04, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Result - GuruFocus.com

Nov 04, 2024

Oct 31, 2024

Trevi Therapeutics (TRVI) Set to Announce Earnings on Wednesday - MarketBeat

Oct 31, 2024

Oct 30, 2024

Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - StreetInsider.com

Oct 30, 2024

Oct 30, 2024

Trevi Therapeutics Adds Clinical Development Expertise in Chroni - GuruFocus.com

Oct 30, 2024

Oct 23, 2024

Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. - Yahoo Finance UK

Oct 23, 2024

Oct 22, 2024

Trevi Therapeutics shares retain buy rating on Haduvio prospects By Investing.com - Investing.com UK

Oct 22, 2024

Oct 22, 2024

Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC Wainwright - MarketBeat

Oct 22, 2024

Oct 21, 2024

Trevi Therapeutics completes enrollment for Phase 2a trial - Investing.com

Oct 21, 2024

Oct 21, 2024

Trevi Therapeutics completes enrollment for Phase 2a trial By Investing.com - Investing.com Australia

Oct 21, 2024

Oct 21, 2024

Trevi Therapeutics, Inc. Completes Enrollment in the Phase 2A RIVER Trial of Haduvio - Marketscreener.com

Oct 21, 2024

Oct 21, 2024

Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - Citizentribune

Oct 21, 2024

Oct 19, 2024

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat

Oct 19, 2024

Oct 18, 2024

TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail

Oct 18, 2024

Oct 15, 2024

Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Citizentribune

Oct 15, 2024

Oct 09, 2024

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance

Oct 09, 2024

Oct 09, 2024

Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: - GuruFocus.com

Oct 09, 2024

Oct 08, 2024

Oppenheimer maintains Outperform on Trevi Therapeutics on Haduvio potential By Investing.com - Investing.com Canada

Oct 08, 2024

Oct 07, 2024

Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley - MarketBeat

Oct 07, 2024

Oct 04, 2024

Trevi Therapeutics reports progress in clinical trials - Investing.com

Oct 04, 2024

Oct 04, 2024

Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLC - MarketBeat

Oct 04, 2024

Oct 04, 2024

Trevi updates on clinical progress for chronic cough treatment - The Pharma Letter

Oct 04, 2024

Oct 04, 2024

Trevi Therapeutics reports progress in clinical trials By Investing.com - Investing.com UK

Oct 04, 2024

Oct 04, 2024

Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com

Oct 04, 2024

Oct 04, 2024

Trevi Therapeutics shares keep buy rating, positive trials By Investing.com - Investing.com UK

Oct 04, 2024

Oct 04, 2024

Trevi Therapeutics hits 50% enrollment in IPF cough study By Investing.com - Investing.com South Africa

Oct 04, 2024

Oct 03, 2024

Trevi Therapeutics hits 50% enrollment in IPF cough study - Investing.com India

Oct 03, 2024